Pfizer COVID-19 vaccine safety data - Child participants COVID-19 vaccines Main navigation COVID-19 vaccines Pfizer JN.1 COVID-19 vaccine safety data – all participants Pfizer COVID-19 vaccine paediatric formulation (5–11 years) Pfizer XBB.1.5 COVID-19 vaccine Moderna XBB.1.5 COVID-19 vaccine Pfizer bivalent BA.4/5 COVID-19 vaccine Moderna bivalent COVID-19 vaccine Pfizer bivalent BA.1 COVID-19 vaccine Pfizer COVID-19 vaccine adult formulation Moderna COVID-19 vaccine Novavax COVID-19 vaccine AstraZeneca COVID-19 vaccine Influenza vaccines Mpox (monkeypox) vaccine National Immunisation Program schedule vaccines Nirsevimab RSV vaccines Shingrix Data on this page show the responses of individuals aged 5–11 years who received a paediatric 5–11 years formulation of the Pfizer COVID-19 vaccine (monovalent original, XBB.1.5 variant or JN.1 variant) and whose parent or carer completed an AusVaxSafety survey on their behalf sent on day 3 after vaccination. These data provide a profile of what to expect in the days following a child’s Pfizer COVID-19 vaccination and can assist when planning for a child’s COVID-19 vaccination. Data on this page are updated monthly. AusVaxSafety’s active vaccine safety surveillance system complements the enhanced safety surveillance activities of the Therapeutic Goods Administration (TGA). Find out more about how the TGA monitors the safety of vaccines and how you can report side effects on the TGA website. News & events All news & events 14 July 2025 | News Fewer adverse events reported following NIP pneumococcal vaccine change 03 June 2025 | News New AusVaxSafety data confirms Abrysvo RSV vaccine is well tolerated during pregnancy; adverse events comparable to other maternal vaccinations 18 May 2025 | News 2025 Australian flu season: Who should get a flu shot, which vaccines are available and what to expect in the days following your vaccination 31 March 2025 | News AusVaxSafety commences routine surveillance of 2025 seasonal influenza vaccines